Abstract 87P
Background
Systemic anticancer therapies have advanced beyond cytotoxic agents; checkpoint inhibitors have revolutionised cancer therapeutics and are now in routine use across multiple disease sites. The mechanism of action places patients at risk of immune-related (IR) side effects including IR colitis (IRC). The management of IRC is described in guidelines, however, in the UK access to some recommended therapies, particularly for steroid refractory IRC, including vedolizumab, remains unclear. We aimed to evaluate vedolizumab access and usage for IRC in UK hospitals.
Methods
We surveyed the use of vedolizumab across UK hospitals; the questionnaire was available between June and July 2024. Questions were developed to identify current practice focusing on preferred treatment guidelines, access to vedolizumab and treatment pathways. An electronic Microsoft Forms questionnaire was disseminated across 2 platforms; via email to all British Oncology Pharmacy Association (BOPA) members, and via presentation and QR code to Immuno-Oncology Clinical Network (IOCN) members for real-time completion. After removing duplicate hospital entries, data was analysed and grouped into themes.
Results
A total of 74 responses were received: 46% by pharmacists (n=34) and 31% by doctors (n=23). Duplicate hospital sites were subsequently combined, and the remaining 46 responses analysed. 65% hospitals (n=30) use ESMO or Clatterbridge cancer centre IRC guidelines. 93% hospitals (n=43) use infliximab 1st line in steroid refractory IRC. 57% hospitals (n=26) have used vedolizumab for 2nd line use, whilst 11% (n=5) hospitals have used it at any line of their IRC treatment pathway. 22% (n=10) hospitals have never used vedolizumab of which funding, experience, willingness to prescribe and lack of place in existing treatment pathways; are contributing factors.
Conclusions
Vedolizumab is used as a 2nd line option for IRC in over half of responding hospitals, however, there is disparity in its usage. The barriers to implementation appear to be primarily driven by funding, willingness to prescribe and experience. Real-world studies on the efficacy of Vedolizumab are warranted to further establish its place in the IRC pathway to recommend as a treatment option.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
168TiP - A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours
Presenter: Giuseppe Curigliano
Session: Poster Display session
Resources:
Abstract
169TiP - Colorectal carcinoma: Low dose immunotherapy in upfront metastatic d/MMR patients (CLOUD study)
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
177P - Ubiquitous neoantigens as targets for T cell recognition in a patient with metastatic pancreatic neuroendocrine tumour
Presenter: Jean-Benoit Tanis
Session: Poster Display session
Resources:
Abstract
178P - Comprehensive immunophenotype analysis in anti-PD-1 antibody sensitive and resistant syngeneic mouse model unravels perforin-expressing CD4+T cells dominant cytolytic activity
Presenter: Hiroyuki Inoue
Session: Poster Display session
Resources:
Abstract
179P - Impact of exercise training on tumour-infiltrating T cells in human prostate cancer
Presenter: Louise Lehrskov
Session: Poster Display session
Resources:
Abstract
180P - Chronic circadian disruption promotes melanoma progression by interfering with NK cells
Presenter: Shuwen Xiao
Session: Poster Display session
Resources:
Abstract
181P - Intratumoral heterogeneity of immune infiltrate in leiomyosarcomas
Presenter: Iva Benesova
Session: Poster Display session
Resources:
Abstract
182P - Innovative nano-immunotherapy for modulating tumor-immune interactions and microbiome in pancreatic cancer
Presenter: Liane Moura
Session: Poster Display session
Resources:
Abstract
183P - CAIX negatively modulates inflammatory and anti-tumor immune responses
Presenter: Eliska Svastova
Session: Poster Display session
Resources:
Abstract
184P - Alterations in tumorigenicity and immunogenicity of bladder cancer cells after somatic cell reprogramming
Presenter: Banu Iskender Izgi
Session: Poster Display session
Resources:
Abstract